Pfizer Warning Letter Shows Challenges Of Upgrading AER Systems
Executive Summary
FDA's warning letter to Pfizer about failures in its post-market adverse event reporting process illustrates the increasing demands that corporate systems are coming under as the agency requests more specific data about patient experiences
You may also be interested in...
Sanofi Still Needs Fix For Adverse Event Reporting As FDA Seeks Retrospective Study, Pinches Accenture
FDA's warning letter to Sanofi-Aventis US over the firm's failure to resolve problems that have delayed adverse event reporting shows the agency is emphasizing the issue in its compliance efforts – and becoming more pointed in its requests for fixes.
Sanofi Still Needs Fix For Adverse Event Reporting As FDA Seeks Retrospective Study, Pinches Accenture
FDA's warning letter to Sanofi-Aventis US over the firm's failure to resolve problems that have delayed adverse event reporting shows the agency is emphasizing the issue in its compliance efforts – and becoming more pointed in its requests for fixes.
FDA's Warning On Postmarketing Adverse Event Reporting To Actelion Signals Enforcement Trend
While still much less frequent than GMP warning letters, PADE letters are on the rise, with FDA focusing on reports for drugs with known serious safety issues.